Health Canada Summary Reports Guidance in Force 1 October 2026: What DIN and NPN Holders Must Change

On 1 October 2026, Health Canada's updated Guidance on preparing and submitting summary reports for marketed drugs and natural health products comes into effect, replacing the version published on 23 May 2018. For every company that holds a Drug Identification Number (DIN) or a Natural Product Number (NPN), this changes a standing post-market obligation. It does not remove it.

The headline that will travel fastest is that annual summary reports now go to the Minister only when Health Canada asks for them in writing. That is true, and it matters. What matters just as much is the part that did not change: the legal duty to prepare an annual summary report every year, for every product you sell in Canada, is unchanged. Reading the update as permission to stop preparing summary reports is the single most expensive mistake a company can make with it.

Executive summary

What is it? An updated Health Canada guidance that clarifies long-standing summary reporting rules rather than rewriting them. Manufacturers and licence holders must still prepare an annual summary report (ASR) each year and still conclude whether there has been a significant change to a product's risks and benefits. The change is to submission: annual reports are provided to Health Canada only on written request, and significant changes are notified through a new form, only when a defined threshold is met.

Health Canada frames the update as part of its red tape reduction efforts, intended to reduce burden by minimizing duplicate reporting and over-reporting, while reinforcing a lifecycle approach within the current regulatory frameworks. The proposed updates were published in October 2025 for a 60-day consultation that drew 132 comments. The table below sets out the essentials at a glance.

What the updated guidance changes, and what it does not

Why does it matter? Because the change is procedural, not substantive. The obligations that create legal exposure, preparing a report and judging significant change, are untouched. If your standard operating procedures describe an automatic annual submission to Health Canada, they now describe a step that no longer exists. If they describe the duty to prepare and retain the report, they are still correct. The distinction decides whether your update is a small edit or an accidental removal of a legal control.

You still have to prepare summary reports every year

What should companies do? Treat preparation as a continuing legal duty and submission as an event triggered by Health Canada. Health Canada describes the duty to prepare annual summary reports as a long-standing requirement that it is merely clarifying. The report must still be prepared, completed, retained and available. It is the routine submission of that report to Health Canada that becomes an on-request activity.

This is the part of the update most likely to be misread. A company that quietly retires its summary report process because it no longer files the report each year will still be non-compliant, because the preparation obligation is set in regulation, not in the guidance. Health Canada can request the report in writing at any time, and a company that has not prepared it cannot produce it. Preparation is also the mechanism through which you reach the conclusion that triggers a significant-change notification, so stopping preparation quietly disables a mandatory safety trigger as well.

Annual summary reports under the Food and Drug Regulations

How does it affect compliance? Under section C.01.018 of the Food and Drug Regulations, a market authorization holder must prepare an annual summary report of all information relating to adverse drug reactions and serious adverse drug reactions that it received or became aware of during the previous 12 months, containing a concise, critical analysis. The requirement arises on the date you first sell the product in Canada and continues throughout the product's life cycle.

Section C.01.020 requires you to maintain the annual summary report for at least 25 years after the day it was created. Health Canada advises that the report be prepared within 70 days of the data lock point, on an annual basis regardless of timelines in other jurisdictions. Where possible, data lock points should be harmonized to the international birth date of the active substance, with the EU reference dates list used as a fallback. Relevant Canadian identifiers, such as the DIN, should be included so the report can be linked to the marketed product.

You may use a standardized format. Health Canada encourages the Periodic Benefit-Risk Evaluation Report (PBRER) format defined in ICH E2C(R2), and accepts the Periodic Safety Update Report (PSUR) format used in the European Union, or a non-standardized format that respects the expected content. Reports prepared for a period longer than one year must have their Canadian-specific information annualized. Quality or good manufacturing practice problems are not summary report content unless they result in adverse clinical outcomes, and should be distinguished from ingredient-related safety issues.

Annual summary reports under the Natural Health Products Regulations

The natural health products side runs on the same logic under a different rule. Under section 24(2) of the Natural Health Products Regulations, a licence holder must prepare and maintain a summary report on an annual basis. The report contains a concise, critical analysis of all domestic adverse reactions and foreign serious unexpected adverse reactions reported over the previous 12 months, and the duty begins on the date the product is first sold in Canada.

Health Canada advises that the natural health product annual summary report be prepared within 70 calendar days of the end of the most recent 12-month period, preferably as a cumulative summary from the date of first sale. Two consecutive 6-month summary reports prepared for another regulatory authority may be used to meet the requirement. As with drugs, the PBRER format is preferred, the PSUR format is acceptable, and a global report covering more than one year must have its Canadian-specific information annualized.

Notifying Health Canada of a significant change

What should companies do? Notify the Minister in writing, without delay, whenever preparing a report leads you to conclude that there has been a significant change in what is known about a product's risks and benefits, using the new notification form and only where the change meets the threshold in the definition. For drugs, this notification is a regulatory requirement; for natural health products, Health Canada encourages it. The conclusion can occur at any time during preparation, so the report does not need to be complete for the duty to notify to arise.

The threshold is a judgement call, and it is exactly where companies get it wrong. Health Canada frames a significant change as one a reasonable person with objective knowledge of credible facts would treat as warranting urgent action, judged on clinical significance. Examples include the need to add serious boxed warnings, precautions or contraindications, add child safety features to packaging, communicate risks to the public or health professionals, or add risk minimization measures such as a pregnancy prevention program or controlled distribution. Quality and GMP issues are out of scope of this notification and should not be reported this way.

For drugs, the notification form is submitted through the Electronic Submissions Gateway. For natural health products, the form is available on request by email from Health Canada's Marketed Health Products Directorate. You do not need to notify twice for the same change: a significant change already reported through a foreign action notification, a labelling or packaging submission, or an updated risk management plan does not require a separate notification, provided it relates to the same change.

How this fits Health Canada's 1 October 2026 changes

The summary reports guidance does not arrive alone. It shares its 1 October 2026 effective date with a cluster of Health Canada instruments, including the revised foreign-action notification requirements and the new C.01.050 list. The two connect directly: a foreign regulator's action on the same safety issue can satisfy both the foreign action notification under C.01.050 and the significant-change notification, which is why the guidance tells you not to notify twice for the same change.

Read together, these changes reinforce a lifecycle approach to regulating drugs and natural health products, in which post-market vigilance, terms and conditions and, for products with EU exposure, European inspection expectations, move in the same direction: targeted, risk-based oversight that assumes your systems and documentation are ready when the regulator asks.

Compliance checklist

Use this checklist to confirm your post-market reporting is ready for the guidance in force 1 October 2026.

• Confirm you continue to prepare an annual summary report for every product you sell in Canada, on a rolling annual basis, whether or not Health Canada has requested it.
• Update SOPs so preparation is a continuing duty and submission is an on-request activity, and remove any language that describes an automatic annual filing to Health Canada.
• Set data lock points, target preparation within 70 days (drugs) or 70 calendar days of the 12-month period (natural health products), and record the format used (PBRER preferred, PSUR acceptable).
• Confirm records are retained for at least 25 years for drugs under C.01.020, and maintained under the NHPR for natural health products.
• Define and document your significant-change threshold, name the decision-maker, and build the new notification form into the workflow so a conclusion reached mid-preparation triggers a notification without delay.
• Map the overlap with foreign action notification (C.01.050), labelling and packaging submissions, and risk management plan updates, so the same change is not notified twice and none of the triggers is missed.
• Confirm you can produce a complete, current annual summary report on written request within a defensible timeframe, and that a designated contact receives and actions Health Canada requests.

Common mistakes

• Reading on-request as optional. The report must still be prepared every year; only the routine submission changed.
• Deleting the process from SOPs. Retiring the summary report procedure disables the significant-change trigger, which is a mandatory safety obligation.
• Substituting the report for the notification. Sending an annual summary report does not discharge the duty to notify a significant change on the new form.
• Waiting until the report is complete to notify. A significant-change conclusion can be reached mid-preparation, and the duty to notify without delay arises then.
• Over-notifying. Notifying changes that do not meet the threshold, or routing quality and GMP issues through this form, works against the guidance and burdens your own team.
• Losing the retention clock. Fewer routine submissions can mean weaker version control; the 25-year retention duty for drug reports does not relax.

Frequently asked questions

Do I still have to submit annual summary reports to Health Canada?

Not routinely. From 1 October 2026, annual summary reports are provided to the Minister only on written request from Health Canada. You must still prepare the report every year and retain it, and you must still notify Health Canada of a significant change to a product's known risks and benefits.

When does the updated guidance take effect?

It comes into effect on 1 October 2026 and replaces the version published on 23 May 2018. Refer to the current version until then.

Which products are covered?

Pharmaceutical drugs (prescription and non-prescription), biologics listed in Schedule D, radiopharmaceuticals in Schedule C, natural health products defined in the NHPR, and combination products. Blood and blood components, cells, tissues and organs, biocides, and sperm and ova are outside the scope of this guidance.

What counts as a significant change?

A change in what is known about a product's risks and benefits that would warrant urgent action, judged on its clinical significance from the perspective of a reasonable person with objective knowledge of credible facts. Examples include adding boxed warnings or contraindications, adding child safety packaging features, communicating risks to the public, or adding risk minimization measures. Quality and GMP issues are not notified this way.

How long must I keep an annual summary report?

For drugs, section C.01.020 of the Food and Drug Regulations requires you to maintain the annual summary report for at least 25 years after the day it was created. Natural health product licence holders must prepare and maintain the report under the NHPR.

What format should the report use?

Health Canada encourages the PBRER format defined in ICH E2C(R2). The EU PSUR format is acceptable and comparable, and a non-standardized format is permitted if it respects the expected content. A report covering more than one year must have its Canadian-specific information annualized.

How MFLRC can help

Your summary report SOPs were written for the 2018 guidance. From 1 October 2026, they describe an obligation that no longer works the way they say. MFLRC reviews your post-market reporting procedures against the updated guidance and rewrites what needs rewriting, before Health Canada's first written request arrives. Our work spans SOP development and remediation, post-market surveillance and pharmacovigilance program design, regulatory affairs and licensing support, gap assessments, and compliance-as-a-service retainers for DIN and NPN holders.

We also help teams define a defensible significant-change threshold, build the new notification form into their workflow, and connect summary reporting to their wider vigilance and CAPA systems so nothing falls between the report, the notification and the risk management plan.

Conclusion

The updated summary reports guidance is a genuine reduction in routine paperwork, but only for companies that read it precisely. The duty to prepare an annual summary report every year, to retain it, and to notify a significant change without delay all remain. The change is that the annual report goes to Health Canada on request, and significant changes go on a new form when they meet the threshold. The companies that benefit are the ones whose procedures reflect that distinction before 1 October 2026, not the ones who discover it during a written request.

Sources and references

• Health Canada, Updated guidance on preparing and submitting summary reports for marketed drugs and natural health products: Notice
• Health Canada, Guidance on preparing and submitting summary reports for marketed drugs and natural health products: Overview (in force 1 October 2026)
• Food and Drug Regulations, section C.01.018 (annual summary report), Justice Laws Website
• Natural Health Products Regulations (SOR/2003-196), section 24, Justice Laws Website
• Health Canada, Good pharmacovigilance practices (GVP) guidelines (GUI-0102)